Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Evaluating Selective Minimal Residual Disease Directed Adjuvant Radiation in Human Papilloma Virus Associated Oropharynx Carcinoma

NCT05307939 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT05307939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05307939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Evaluating Selective Minimal Residual Disease Directed Adjuvant Radiation in Human Papilloma Virus Associated Oropharynx Carcinoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
March 24, 2022
Completion date
March 24, 2027
Enrollment
30 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hpv, hpv positive oropharyngeal squamous cell carcinoma, hpv-related carcinoma, hpv-related malignancy, oropharynx cancer